Neuralstem in the News
Neuralstem, NFL Alumni Association To Test Feasibility Of Traumatic Brain Injury Treatment
Neuralstem’s NSI-189/traumatic brain injury initiative announcement with the NFLA received widespread coverage, including this posting to The Huffington Post.
Football and Concussions: New Drug To Be Tested on NFL Alumni
The promise of hope for “Finally, a possible solution to contact sport related head injuries” is cited in this article which highlights Neuralstem’s and the NFLA’s new initiative to develop a trial to treat traumatic brain injury for former NFL players.
Michigan University Joins Lou Gehrig’s Clinical Trial
Robin Erb’s NSI-566/ALS Phase II FDA-approval feature story in Detroit Free Press (4/17/13) ran in USA Today. Added Story Highlights sidebar cites dual clinical trial centers; no current cure for ALS, and the study’s “one of a kind” cell therapy.
Neuralstem Expands Lou Gehrig’s Disease Trials
Rockville, Maryland-based Neuralstem’s NSI-566/ALS Phase II trial’s approval by the FDA was reported in the D.C. region business journal.
U-M May Recruit ALS Patients for Stem Cell Clinical Trial
“We need ALS research fast-tracked… This isn’t even about a cure. People would be happy with the treatment.” NSI-566/ALS principal investigator, Eva Feldman, M.D., Ph.D., spoke with Robin Erb for a feature following her initial breaking news story on the Phase II FDA green-light.
Select media coverage in this website is provided for the information and convenience of the public, and is not intended to be all-encompassing nor an endorsement of the specific stories or media outlets.